BioWorld

Jan. 31, 2002

Amylin Seeks $92M Publicly To Fund AC2993 Phase IIIs

Amylin Pharmaceuticals Inc. started the second of three Phase III trials on AC2993, a compound designed to treat people with Type II diabetes by improving glucose control. (BioWorld Today) Read More

Signature Continues Acquisitions, Buys PDL’s Small-Molecule Unit

Signature BioScience Inc. is moving toward drug discovery and fueling the trek with acquisitions. (BioWorld Today) Read More

Scar Tissue In Injured Spinal Cord Acts As Barrier Preventing Normal Regeneration, Functional Recovery

IntraBiotics Netting $13.9M From Private Deal For Iseganan Studies

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...